-

ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference.

Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event on Thursday, May 18, 2023.

To arrange a meeting with the ChromaDex management team, please contact Lytham Partners at 1x1@lythampartners.com, or register online by clicking the link here: ChromaDex Investor Meetings - Lytham Partners.

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Contacts

ChromaDex Media Contact:
Kendall Knysch, Director of Media Relations
310-388-6706 ext. 689
kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:
+1 (949) 356-1620
InvestorRelations@ChromaDex.com

Industry:

ChromaDex Corporation

NASDAQ:CDXC
Release Versions
English
$Cashtags
$CDXC
Hashtags
#ChromaDex
#IRChat
#LythamIR
#NAD
#NR
#TruNiagen
#investorrelations
#lythamspring2023

Contacts

ChromaDex Media Contact:
Kendall Knysch, Director of Media Relations
310-388-6706 ext. 689
kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:
+1 (949) 356-1620
InvestorRelations@ChromaDex.com

Social Media Profiles
ChromaDex Facebook
ChromaDex Linkedin
ChromaDex Twitter
More News From ChromaDex Corporation

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside in the Company’s flagship ingredient, Niagen®, now has a published United States Pharmacopeia (USP) dietary supplement ingredient monograph. This monograph reflects the scientific rigor behind Niagen and establishes...

Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced OneSpaWorld (NASDAQ: OSW) as the newest Niagen Plus™ provider, engaged to offer pharmaceutical grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships. Marking Niagen Bioscience’s first cruise ship clinic partnership, this collaboration brings Niagen IV to guests at sea. Rob Fried, C...

Niagen Bioscience Increases Share Repurchase Program to $20 Million

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an increase to the Company’s previously disclosed share repurchase program (the “Program”), raising the total authorization from $10 million to $20 million of the Company's outstanding common stock. Through March 17, 2026, the Company has repurchased approxim...
Back to Newsroom